Neurocrine Biosciences
NBIX
NBIX
596 hedge funds and large institutions have $12.9B invested in Neurocrine Biosciences in 2024 Q4 according to their latest regulatory filings, with 112 funds opening new positions, 212 increasing their positions, 210 reducing their positions, and 73 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
1.11% more ownership
Funds ownership: 92.1% → 93.21% (+1.1%)
9% more call options, than puts
Call options by funds: $48M | Put options by funds: $44.2M
1% more repeat investments, than reductions
Existing positions increased: 212 | Existing positions reduced: 210
Holders
596
Holding in Top 10
12
Calls
$48M
Puts
$44.2M
Top Buyers
| 1 | +$236M | |
| 2 | +$106M | |
| 3 | +$101M | |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$97.2M |
| 5 |
AC
Armistice Capital
New York
|
+$97M |
Top Sellers
| 1 | -$84.4M | |
| 2 | -$67.1M | |
| 3 | -$62.4M | |
| 4 |
DM
Deerfield Management
New York
|
-$62.1M |
| 5 |
Amundi
Paris,
France
|
-$54.8M |